Mónica L Fanarraga | Nanobiotechnology | Excellence in Research

Posted on by ScienceFather

Prof Dr. Mónica L Fanarraga | Nanobiotechnology | Excellence in Research

Prof Dr. Mónica L Fanarraga, Universidad de Catabria, Spain

👩‍🔬 Prof. Dr. Mónica L. Fanarraga🎓 An esteemed researcher and Professor at the University of Cantabria, Spain, Dr. Mónica L. Fanarraga is a trailblazer in nanomedicine. With dual PhDs in Biology and Medicine/Surgery, she founded the “Nanomedicine” research group at IDIVAL Institute. Over 40 competitive projects and 70 JCR publications showcase her impact. Recognized with the “Best Researcher Award” in 2022, she mentors researchers and champions innovation. Dr. Fanarraga’s recent projects secured substantial funding, affirming her dedication to cutting-edge nanomedicine research. Her contributions extend to patents, including groundbreaking work on silica nanoparticles, emphasizing her commitment to advancing scientific knowledge for over 30 years. 🌐🔬🏆

🏫 Education & Experience:

🎓 Degrees in Veterinary Medicine (1989). 📚 Dual PhDs in Biology (1993) and Medicine and Surgery (1999). 🧪 Founder of the “Nanomedicine” research group at IDIVAL Institute, Santander, Spain. 👩‍🏫 Current Professor at the University of Cantabria. 🏆 “Best Researcher Award” from Fenin (Spanish Platform for Innovation in Health Technology, 2022).

🔬 Academic Achievements:

🌐 Spearheaded over 40 competitive research projects in nanobiotechnology. 📚 Published 70+ JCR publications in esteemed journals. 📝 Principal Investigator for articles in journals like Adv. Healthc. Mat., J.Nanobiotech, Angewandte Chem, Nature, ACS Nano. 🏅 Secured 5 patents in the field of nanomedicine. 🎓 Mentored 10 postdoctoral researchers and supervised 14 defended doctoral theses. 🏅 6 theses received the “Extraordinary Prize,” 2 awarded the “Juan Mª Parés” Prize.

💡 Contributions to Research & Development:

🌟 Led successful projects, including TED2021-129248B-I00, securing €426,650 in funding. 💰 Secured funding for various Innovation projects, ranging from €15,000 to €56,100. 🌍 Actively involved in mentoring young scientists for national and international postdoctoral initiatives. 🏆 Key role in Marie Curie H2020-MSCA-IF-2019 project (€62,220) and Horizon-MSCA-Doctoral Networks 2021 project (€250,000).

🧪 Innovations in Nanomedicine:

🧬 Pioneering work on silica nanoparticles for nucleic acid encapsulation (2021). 🔄 Innovative approaches in protein (2017) and carbon nanotube conjugation of nanomaterials (2017). 🧠 Contributions to neurodegenerative disease research and advancements in gene transfer methods showcase continuous efforts in pushing scientific boundaries over 30 years.

Professional Profiles:

The impact of her research is evident in citation metrics and indices from Google Scholar:

  • Cited by: All – 2906.
  • Citations – 2906.
  • h-index – 29.
  • Documents – 100.

A prolific researcher making meaningful contributions to the academic world!

🔬 Research Focus:

🔍 Prof Dr. Fanarraga has made significant contributions in the fields of cell biology and nanomedicine. Her pioneering work encompasses critical areas such as organelle transport, microtubule dynamics, and controlled drug delivery systems. With a remarkable citation record, her impactful studies on dynactin’s role in bidirectional organelle transport (399 citations) and the uncoupling of hypomyelination and glial cell death (238 citations) showcase her expertise in cell biology. Additionally, her exploration of postchaperonin tubulin folding cofactors (163 citations) and their role in microtubule dynamics demonstrates a multifaceted approach to understanding cellular processes. Dr. Fanarraga’s diversified research extends to innovative applications, including magnetic hyperthermia-enhanced cell toxicity (125 citations) and the use of carbon nanotubes in mimicking microtubule properties (81 citations). Her extensive body of work reflects a commitment to advancing knowledge at the intersection of cellular biology and nanomedicine. 🌐🔬

Publications Top Note:

Jennifer Mahony | Nanobiotechnology | Best Researcher Award

Posted on by ScienceFather

Prof. Jennifer Mahony | Nanobiotechnology | Best Researcher Award

Prof. Jennifer Mahony, University College Cork, Ireland

👩‍🔬 Prof. Jennifer Mahony is a distinguished academic and researcher at University College Cork, Ireland. With a Ph.D. in Molecular Microbiology, she has led impactful research in microbiology, specializing in dairy starter and adjunct bacteria diversity, bacteriophages of lactic acid bacteria, and anti-microbial producing bacteria. As the Chair of the Equality, Diversity, and Inclusion (EDI) committee, she contributes to a more inclusive academic environment. Prof. Mahony’s commitment extends to editorial roles in prestigious journals and active involvement in academic leadership and student mentoring. Her expertise in food microbiology is complemented by a passion for teaching, reflected in her engaging lectures and supervision of research projects. 🌐🔬👩‍🏫

🎓 Education:

Ph.D. in Molecular Microbiology, School of Microbiology, University College Cork (2008). B.Sc. in Applied Biosciences, Cork Institute of Technology (2003, Graduated first in class). Postgraduate Diploma (2020/21) and Certificate (2018) in Teaching and Learning, University College Cork. Certificate in Amenity Horticulture, Coláiste Stiofáin Naofa, Cork (1997, Graduated first in class).

👩‍🏫 Employment:

Professor of Molecular Food Microbiology, School of Microbiology, UCC (2021-present). Lecturer in Food Microbiology, School of Microbiology, UCC (2020-2021). Research Fellow & Starting Investigator, School of Microbiology, UCC (2016-2019). Junior (2008-2012) /Senior (2012-2014) Post-doctoral Researcher, School of Microbiology, UCC (2008-2014).

🌐 Other Activities:

Chair of the EDI Committee for the College of Science, Engineering, and Food Science (2023-present). Chair of the School of Microbiology Athena Swan self-assessment team (2020-2023). Associate Editor, Microorganisms (2021-present). Associate Editor, BMC Microbiology (areas of applied & food microbiology) (2017-2023). Member of APC Microbiome Ireland, Operations Management Group (2017-present).

🔬 Research Interests:

Specializes in microbiological and molecular approaches to defining diversity and interactions of dairy starter and adjunct bacteria. Focuses on bacteriophages of lactic acid bacteria, development of robust starter cultures, and isolation of novel antimicrobial-producing bacteria.

👩‍🏫 Teaching & Examining Experience:

Extensive experience in delivering, examining, and designing undergraduate modules. Supervises final year projects and provides guidance for student literature reviews. Examiner for various modules, research MSc theses, and Ph.D. defenses globally.

🌐 Contributions:

Actively contributes to enhancing diversity in academia as the Chair of the EDI Committee. Plays a pivotal role in the advancement of microbiology through editorial responsibilities and involvement in research groups.

Professional Profiles:

The impact of her research is evident in citation metrics and indices from Google Scholar:

  • Cited by: All – 7501.
  • Citations – 7501.
  • h-index – 43.
  • Documents – 179.

A prolific researcher making meaningful contributions to the academic world!

🔬 Research Focus:

Prof. Jennifer Mahony is a distinguished researcher with a primary focus on understanding and unraveling the intricacies of microbial ecosystems. Her extensive contributions encompass the exploration of the first microbial colonizers of the human gut, investigating their composition, activities, and health implications in infant gut microbiota. Additionally, her research delves into the realms of T-cell activation by transitory neo-antigens, antifungal lactic acid bacteria as bio-preservatives, and the biocontrol potential of bacteriophages against food pathogens. With a keen interest in glycan utilization, cross-feeding activities, and phage biology, Prof. Mahony’s work significantly advances our comprehension of microbial interactions in various environmental niches.

Publications Top Note:

Kristiina Maria Huttunen | Nanobiotechnology | Best Researcher Award

Posted on by ScienceFather
Assoc Prof Dr. Kristiina Maria Huttunen: Nanobiotechnology

Dr. Kristiina Maria Huttunen, born on May 7, 1980, in Taipalsaari, Finland, is an accomplished researcher specializing in drug targeting and nanochemistry. A native Finnish speaker with excellent proficiency in English, and proficiency in Swedish and basic skills in German, she is an Associate Professor at the University of Eastern Finland (UEF), leading the Transporter-mediated Drug Delivery group.

🎓 Education:

Docent Drug Targeting (Adjunct/Associate Professor): University of Eastern Finland, 2015. Ph.D. in Pharmaceutical Chemistry: University of Kuopio, 2009 (Best Thesis of the University 2008-2009). M.Sc. in Medicinal Chemistry: University of Kuopio, 2004. B.Sc. in Chemistry: University of Jyväskylä, 2003

👩‍🏫 Teaching & Continuing Education:

Course Director for Organic Chemistry (from 2023). Various teaching roles since 2005. Continued education in leadership and pedagogy.

🏢 Current Position (in Finland):

University: University of Eastern Finland. Faculty: Faculty of Health Sciences, School of Pharmacy. Position: Associate Professor (Tenure Track) and Principal Investigator (PI). Group: Leader of Transporter-mediated Drug Delivery Group (9 members). Commencement: 1st December 2023.

📚 Previous Work Experience:

Research Director, University Researcher, and Academy Research Fellow at UEF. Postdoctoral Research positions in Finland and New Zealand. Research Scientist and Ph.D. Student at the University of Kuopio.

👩‍🔬 Supervision & Teaching Experience:

Supervised numerous graduate and undergraduate students. Diverse teaching roles in organic chemistry and pharmaceutical courses.

💰 Research Funding:

PI for Project Grants totaling €3,060,733. Supervised student grants totaling €612,757. Postdoctoral and Ph.D. student grants.

👩‍💼 Institutional Responsibilities and Commissions of Trust:

Board Member, Faculty Council, and Doctoral Programme in Drug Research. Active involvement in brain barrier and brain tumor research associations. Reviewer for scientific journals and external reviewer for research plan defenses.

🔍 Scientific and Societal Impact (2004 – present):

77 Peer-reviewed original publications, 16 review articles. Invited speaker at 20 national/international conferences and seminars. Webpages and blog for open science communication. Patents and invention disclosures. Extensive engagement in general audience publications and interviews.

Professional Profiles:

The impact of her research is evident in citation metrics and indices from Google Scholar:

  • Cited by: All – 2,401.
  • Citations – 1595.
  • h-index – 24.
  • Documents – 98.

A prolific researcher making meaningful contributions to the academic world!

Research Focus:

Dr. Assoc Prof Dr. Kristiina Maria Huttunen research revolves around understanding brain barrier transporters and their role in drug delivery. Their work spans the structural comparison of sulfonamide-based derivatives, exploration of experimental strategies for studying amino acid transporter utilization, and the intricate relationship between neurosteroids and organic anion transporting polypeptides (OATP)1A2.

Publications Top Note:

 

 

Prof. Funan Liu | Nanobiotechnology

Posted on by ScienceFather
Prof. Funan Liu: Oncolytic Virus

Congratulations, Prof. Funan Liu, on winning the esteemed Best Researcher Award from ScienceFather! Congratulations on reaching this significant milestone in your journey. Over the past year, you’ve undoubtedly achieved incredible feats and contributed immensely to your field. Here’s to many more years of success, innovation, and fulfillment in your endeavors. Wishing you continued growth, prosperity, and joy in the years to come. Keep shining and making a difference in the world!

Dr. Funan Liu is a distinguished medical professional, serving as a Professor, Chief Physician, and Doctoral Supervisor. Recognized as a key figure in healthcare, he holds prestigious positions as a Youth Top Talent under Liaoning Province’s ‘Revitalize Liaoning Talent Program’ and China Medical University’s Youth Top Talent. Additionally, he is a candidate in the ‘Hundred Thousand Ten Thousand Talent Project’ at the Thousand-Level. Dr. Liu serves as the Chief of the Phase I Clinical Trial Center at the First Affiliated Hospital of China Medical University. His expertise and leadership contribute significantly to advancing medical research and clinical trials, making him a prominent figure in the field.

Major academic positions:  

As the Deputy Director of the Gastric Cancer Committee for the Chinese Society for the Promotion of Health Science and Technology, Dr. Funan Liu plays a pivotal role in advancing gastric cancer research and awareness. He holds several leadership positions, including Vice Chairman of the 10th Committee of the Surgical Branch in the Liaoning Medical Association, and Standing Committee Member of various prestigious organizations, such as the Integrative Oncology Branch of the Chinese Anti-Cancer Association. Dr. Liu is actively involved in committees related to esophageal cancer, tumor prevention and control, oncology, and colorectal cancer. His extensive engagement underscores his commitment to multidisciplinary collaboration and advancing cancer care in various capacities within medical associations and committees.

Undertaken projects:

Dr. Funan Liu, a prominent researcher and medical professional, has spearheaded numerous groundbreaking projects in the realm of oncology. As a principal investigator, he led two National Key R&D Program research initiatives, focusing on clinical trials and therapeutic mechanisms of novel oncolytic virus cancer treatments, and the clinical evaluation of an in vitro tumor cell drug sensitivity technology system. Simultaneously, Dr. Liu undertook two National Natural Science Foundation of China general projects, investigating pH-sensitive liposome-hybrid red blood cell membrane-coated oncolytic virus intravenous delivery technology and the role of FN1 3’UTR as a new ceRNA in gastric cancer. His comprehensive expertise extends to projects funded by Liaoning Province and the CSCO-Merck Serono Cancer Research Fund, solidifying his impactful contributions to advancing cancer research and treatment.

Hosted and participated in clinical research:

This extensive portfolio of clinical trials reflects a commitment to advancing medical science and improving patient outcomes across various oncological fronts. Driven by cutting-edge research, these trials span from Phase I to Phase III, covering a spectrum of investigational therapies for different types of advanced solid tumors. The studies explore innovative approaches such as immunotherapy combinations, targeted therapies, and novel agents, aiming to enhance treatment efficacy and patient survival. From evaluating the safety, tolerability, and pharmacokinetics of promising compounds like TIRAGOLUMAB and DN015089 to studying the potential benefits of combining checkpoint inhibitors with chemotherapy in gastric cancer (HLX10 trial), these trials address critical gaps in current cancer care.

The diversity of trials encompasses indications like breast cancer, colorectal cancer, gastric cancer, and more, reflecting a comprehensive strategy to combat a range of malignancies. The focus on specific genetic mutations, such as EGFR in cholangiocarcinoma and bladder cancer (AL8326 trial), underscores the importance of personalized medicine in tailoring treatments to individual patient profiles. Additionally, the exploration of novel agents like BC004 injection and TJ033721 reveals a dedication to identifying and developing innovative therapeutic modalities.

These studies not only aim to expand the armamentarium of available treatments but also contribute valuable insights to the evolving landscape of cancer research. By pushing the boundaries of scientific understanding, these clinical trials under the leadership of Dr. Funan Liu hold great promise in shaping the future of oncology and, ultimately, improving the lives of patients grappling with advanced solid tumors.

Professional Profiles:

The impact of her research is evident in citation metrics and indices from Google Scholar:

  • Cited by: All – 1,206.
  • Citations – 1,070.
  • h-index – 22.
  • Documents – 55.

A prolific researcher making meaningful contributions to the academic world!

Publications Top Note:
  1. Engineered bacterial outer membrane vesicles encapsulating oncolytic adenoviruses enhance the efficacy of cancer virotherapy by augmenting tumor cell autophagy
    • Published in Nature Communications in 2023 with 6 citations.
  2. Virus-Protein Corona Replacement Strategy to Improve the Antitumor Efficacy of Intravenously Injected Oncolytic Adenovirus
    • Published in ACS Nano in 2023 with 0 citations.
  3. Antigen-capturing oncolytic adenoviruses along with IDO blockade for improved tumor immunotherapy
  4. Inhibition of Tumor Metastasis by Liquid-Nitrogen-Shocked Tumor Cells with Oncolytic Viruses Infection
    • Published in Advanced Materials in 2023 with 4 citations.
  5. Oncolytic Virus-Driven Biotherapies from Bench to Bedside
    • Published in Small in 2023 with 2 citations.
  6. Self-assembled short peptides: Recent advances and strategies for potential pharmaceutical applications
    • Published in Materials Today in 2023 with 3 citations.
  7. Erythrocyte-Leveraged Oncolytic Virotherapy (ELeOVt): Oncolytic Virus Assembly on Erythrocyte Surface to Combat Pulmonary Metastasis and Alleviate Side Effects
    • Published in Advanced Science in 2023 with 0 citations.
  8. FN1 mRNA 3′-UTR supersedes traditional fibronectin 1 in facilitating the invasion and metastasis of gastric cancer through the FN1 3′-UTR-let-7i-5p-THBS1 axis
    • Published in Theranostics in 2023 with 0 citations.
  9. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
    • Published in Frontiers in Pharmacology in 2023 with 2 citations.
  10. Drug conjugate-based anticancer therapy – Current status and perspectives
    • Published in Cancer Letters in 2023 with 17 citations.